Navigation Links
Amikacin Inhale Shows Promising Results in Phase II Study

- Bayer together with Nektar Therapeutics present preliminary Phase II data

for the adjunctive treatment of pneumonia in intubated and

mechanically-ventilated patients

TORONTO and BERLIN, May 19 /PRNewswire-FirstCall/ -- Bayer HealthCare together with Nektar Therapeutics (Nasdaq: NKTR), today presented positive preliminary Phase II data on their unique drug-device combination Amikacin Inhale at the American Thoracic Society (ATS) annual meeting. Amikacin Inhale, currently being studied for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients, achieved over 1000 times greater lung exposure to the antibiotic amikacin as compared to intravenous route of administration. This shows that targeting antibiotic therapy to the site of infection might offer superior bacterial eradication and increased efficacy, which may result in a higher likelihood of the patient's survival. Currently, Gram-negative pneumonia carries a mortality risk as high as 50 percent in mechanically-ventilated patients(1).

"Mechanically-ventilated patients in critical care units are at particularly high risk of developing pneumonia. Most of them are already seriously ill because of severe underlying diseases," said Professor Michael Niederman, Chairman, Department of Medicine, Winthrop University Hospital, New York, and one of the lead investigators of the study. "Because of the high morbidity and mortality of Gram-negative pneumonia, fast and efficient treatment is essential. Intravenous therapies cannot always reach effective concentrations in infected lungs at tolerable doses. The new study data shows that the device successfully delivers the antibiotic directly to the site of infection, without reaching high systemic concentrations."

Amikacin Inhale is a unique drug-device combination, being developed by Bayer HealthCare in cooperation with Nektar Therapeutics, combining a special liquid formulation of the aminoglycoside antibiotic amikacin with Nektar Therapeutics' proprietary Liquid Pulmonary Technology (LPT(TM)), designed to deliver amikacin deep into the infected lungs.

The device can be integrated into mechanical ventilation systems and can also be used as a handheld 'off-vent' device for patients no longer requiring breathing assistance. This allows for a unique full course of drug therapy in critically ill patients with Gram-negative pneumonia. 'Gram-negative pneumonia' refers to pneumonia caused by a laboratory-defined group of pathogens, the Gram-negative bacteria. These account for a substantial proportion, if not the majority of pneumonias in intensive care units (ICUs).

"A challenge in treating Gram-negative pneumonia in ICUs is that they have grown increasingly resistant to currently available antibiotics," said Professor Donald Low, Head of the Department of Microbiology at the Toronto Medical Laboratories and Mount Sinai Hospital, Toronto, Canada. "A new treatment option such as Amikacin Inhale, which fights pneumonia directly at the site of infection, may be able to help decrease resistance -- especially if concomitant intravenous antibiotic therapy can also be reduced."

Amikacin Inhale will enter Phase III trials later this year to further assess its efficacy and safety in mechanically ventilated patients with Gram-negative pneumonia. The enrolment for two pivotal Phase III studies will start in the fourth quarter of 2008.

About Phase II Studies

High Amikacin Lung Deposition in MVP(2)

In the multi-center, randomized, double-blind, placebo-controlled Phase II study mechanically ventilated patients (MVP) received 400 mg doses of amikacin with Amikacin Inhale every 24 hours (n=24) or every 12 hours (n=21) for 7-14 days.

Serial serum, tracheal aspirate and urine samples were collected on Day 3. Clinical parameters, such as Clinical Pulmonary Infection Score (CPIS), days on ventilator and intravenous antibiotic use were monitored. In another study healthy volunteers (n=14) inhaled a single dose of 400 mg of amikacin via the proprietary delivery system using the hand held adaptor. This was done to compare the lung doses between on-vent and hand-held adaptors using the same proprietary nebulizer.

Mean peak tracheal aspirate of amikacin after Amikacin Inhale use every 12 hours was 16,212 +/- 3,675 mcg/mL as compared to 14 +/- 4.2 mcg/mL after intravenous administration (15mg/kg per day)(3). After Amikacin Inhale use, peak serum levels of amikacin were 3.2 +/- 0.5 mcg/mL versus 47 +/- 4.2 mcg/mL after intravenous administration. On average, 43 percent of the dose was delivered to the lungs using the hand-held system with a comparable low systemic exposure. The dose delivered to the lungs with the proprietary nebulizer is comparable between the on-vent and hand-held adaptors.

Penetration of Amikacin Inhale in Lower Respiratory Tract(4)

This study evaluated Amikacin Inhale penetration into the fluid lining of the epithelial surface (ELF) of the lower respiratory tract of the pneumonia-infected lung. Treatment was adjunctive to IV treatment. Mechanically ventilated patients (n=28) with Gram-negative pneumonia received 400 mg doses of aerosolized amikacin every 12 hours for 7-14 days. The delivery of aerosolized Amikacin Inhale achieved high aminoglycoside amikacin concentrations in the ELF of the lower respiratory tract, including in the pneumonic area of the lung while maintaining safe serum concentrations. Median ELF levels were 976.1 mcg/mL [135.7-16,127.6], always exceeding the amikacin MIC (minimum inhibitory concentration) for microorganisms usually responsible for Gram-negative pneumonia.

High in vivo Amikacin Lung Deposition Correlates with in vitro Findings(5)

This study describes the in-vitro and in-vivo characterization of a handheld version of Amikacin Inhale, intended for use in extubated patients. In-vitro, amikacin 400 mg was aerosolized continuously, and emitted mass captured on absolute filters distal to the mouthpiece during simulated adult tidal breathing. Emitted mass was 87 percent of the 400 mg amikacin nominal dose, with a predicted lung dose of 45-50 percent. In-vivo, Amikacin Inhale (400 mg amikacin) labeled with 99mTc was administered to healthy subjects using the hand-held version. In these, mean amikacin lung dose determined via scintigraphy was 172.2 mg, 43 percent of the nominal dose. These results show that the hand-held drug-device combination delivered a large fraction of the starting dose, confirming the high delivery efficiency predicted by in-vitro aerosol characterization. The study also confirmed that the in-vitro model is predictive of the in-vivo experience. Lung doses in the range of those observed are expected to achieve bacteriological eradiation.

Copies of abstracts are available and can be viewed online at the ATS website:

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases. Find more information at

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its pulmonary and PEGylation technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance. Find more information at


Bayer HealthCare Nektar Therapeutics

Yvonne Moller Stephan Herrera

Tel.: +49 (0) 30 468 17 389 Tel.: +1 (415) 488-7699

E-mail: E-mail:

Forward-Looking Statements

Bayer - This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Nektar - This press release contains forward-looking statements regarding the potential and clinical development plans for Amikacin Inhale. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) Nektar's or its partners' clinical trials may fail to meet minimum clinical end points; (ii) Nektar or its partners may ultimately fail to obtain regulatory approval of one or more product candidates; and (iii) the timing or success of commencing or concluding clinical trials is subject to a number of risks uncertainties including but not limited to clinical trial design, patient enrollment, regulatory requirements, manufacturing scale-up and clinical outcomes. These forward-looking statements involve substantial risks and uncertainties, including those risks and uncertainties that are detailed in Nektar's reports and other filings with the SEC including its most recent Quarterly Report on Form 10-Q filed on May 9, 2008. Actual results could differ materially from the forward-looking statements contained in this press release. Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events, or otherwise. No information regarding or presented at the medical and scientific meetings referred to above (or contained at the Internet links provided) is intended to be incorporated by reference in this press release.

(1) Chastre J & Fagon J-Y. Am J Respir Crit Care Med 2002;165:867-903

(2) Corkery K, et al. Evidence of High Amikacin Lung Deposition in

Mechanically Ventilated Patients (MVP) with Pneumonia and Healthy

Subjects (HS) dosed using NKTR-061. Poster 517 American Thoracic

Society International Conference, May 19, 2008

(3) Santre C. Georges H, Jacquier JM, Leroy O , Beuscart C, Buguin D,

Beaucarie G et al, Amikacin levels in bronchial secretions of 10

pneumonia patients with respiratory support treated once daily versus

twice daily. Antimicrob Agents Chemother 1995; 39:264-7

(4) Luyt CE, et al. NKTR-061 (inhaled amikacin) BID achieves high

epithelial lining fluid concentrations in pneumonic portions of lung.

Poster 516 American Thoracic Society International Conference, May 19,


(5) J. Fink, MS, et al. High in vivo Amikacin Lung Deposition after

NKTR-061 dosing correlates with in vitro aerosol characterization.

Poster 518 American Thoracic Society International Conference, May 19,


SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
2. Inhaled Steriods Used as Preventive Treatment Post 9/11
3. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
4. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
5. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
6. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
7. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
8. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Post Your Comments:
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... Research and Markets has announced the addition of the "Global ... and Increasing Usage of Complex Biologics during the Forecast Period" ... The ... Billion in 2015 to around USD 26 Billion by 2020. ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology:
(Date:4/28/2017)... R.I. (PRWEB) , ... April 28, 2017 , ... Getting enough sleep affects much more ... Foundation (NSF), going just 19 hours without sleep can compromise motor reaction time, which can ... Week, and Amica Insurance is sharing the following tips from the NSF to help you ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... People are ... older people. “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa ... Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec ... Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates to their ... expert that specializes in long-term care, Brooke Grove now has the capability to ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Christie ... today announced an alliance with B. Braun Medical Inc. , a leader in ... in patient care with as many as 90 percent of hospital patients receiving a ...
Breaking Medicine News(10 mins):